These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 23796793)

  • 1. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.
    Ladabaum U; Allen J; Wandell M; Ramsey S
    Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1567-76. PubMed ID: 23796793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
    Sharaf RN; Ladabaum U
    Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of colorectal cancer screening in Germany: current endoscopic and fecal testing strategies versus plasma methylated Septin 9 DNA.
    Ladabaum U; Alvarez-Osorio L; Rösch T; Brueggenjuergen B
    Endosc Int Open; 2014 Jun; 2(2):E96-E104. PubMed ID: 26135268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood.
    Payne SR
    Epigenomics; 2010 Aug; 2(4):575-85. PubMed ID: 22121975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer.
    Warren JD; Xiong W; Bunker AM; Vaughn CP; Furtado LV; Roberts WL; Fang JC; Samowitz WS; Heichman KA
    BMC Med; 2011 Dec; 9():133. PubMed ID: 22168215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SEPT9: A Specific Circulating Biomarker for Colorectal Cancer.
    Song L; Li Y
    Adv Clin Chem; 2015; 72():171-204. PubMed ID: 26471083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality.
    D'Andrea E; Ahnen DJ; Sussman DA; Najafzadeh M
    Cancer Med; 2020 Jan; 9(2):824-836. PubMed ID: 31777197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of
    Sun J; Fei F; Zhang M; Li Y; Zhang X; Zhu S; Zhang S
    BMC Cancer; 2019 May; 19(1):450. PubMed ID: 31088406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study.
    Ørntoft MB; Nielsen HJ; Ørntoft TF; Andersen CL;
    BMC Cancer; 2015 Oct; 15():819. PubMed ID: 26514170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy.
    Ladabaum U; Mannalithara A; Weng Y; Schoen RE; Dominitz JA; Desai M; Lieberman D
    Gastroenterology; 2024 Jul; 167(2):378-391. PubMed ID: 38552670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer.
    deVos T; Tetzner R; Model F; Weiss G; Schuster M; Distler J; Steiger KV; Grützmann R; Pilarsky C; Habermann JK; Fleshner PR; Oubre BM; Day R; Sledziewski AZ; Lofton-Day C
    Clin Chem; 2009 Jul; 55(7):1337-46. PubMed ID: 19406918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals.
    Ladabaum U; Mannalithara A; Jandorf L; Itzkowitz SH
    Cancer; 2015 Apr; 121(7):1088-97. PubMed ID: 25492455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
    Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
    Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
    Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
    Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of Colorectal Cancer Using a Simplified SEPT9 Gene Methylation Assay Is a Reliable Method for Opportunistic Screening.
    Wu D; Zhou G; Jin P; Zhu J; Li S; Wu Q; Wang G; Sheng J; Wang J; Song L; Han X; Qian J
    J Mol Diagn; 2016 Jul; 18(4):535-45. PubMed ID: 27133379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests.
    Peterse EFP; Meester RGS; de Jonge L; Omidvari AH; Alarid-Escudero F; Knudsen AB; Zauber AG; Lansdorp-Vogelaar I
    J Natl Cancer Inst; 2021 Feb; 113(2):154-161. PubMed ID: 32761199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
    Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
    Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.